ClinicalTrials.gg
Not yet recruitingNCT07313917Updated Feb 6, 2026

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

A Phase 2 interventional study of LP-003 Injection and Placebo of LP-003 in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Longbio Pharma. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Planned enrollment
14th of 43
150 · median 90
Started
2026
with 9 others
Phase 2
13 of 46
4 open now
Primary completion
2027-02
later than 11 of 23 live
Registered
37th of 46
by date

Among the 46 studies in Nasal Polyps with a site in China, this one is the 14th largest by planned enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 11 of the 23 other live ones, and was the 37th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding the study and voluntarily signing the Form (ICF);
  2. Aged 18 to 75 years (inclusive) at the time of signing the ICF, regardless of gender;
  3. Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP);
  4. Persistence of the following symptoms for ≥ 4 weeks prior to the screening/run-in period:

    • Nasal congestion;
    • Any one of the other symptoms: mucoid or mucopurulent nasal discharge, head and facial distension/pain, hyposmia or anosmia;
  5. Nasal Polyp Score (NPS) ≥ 5 points, with each nasal cavity scoring at least ≥ 2 points during the screening/run-in period and prior to randomization;
  6. Participants report moderate to severe nasal congestion during the screening/run-in period and prior to randomization:

    • Nasal Congestion Score (NCS) of 2 or 3 points at the screening/run-in period (Visit 1, V1);
    • Mean weekly NCS ≥ 2 points prior to randomization;
  7. With bilateral CRSwNP despite prior treatment with systemic (SCS) such as oral corticosteroids (OCS) within 2 years prior to screening; and/or has to SCS treatment or is intolerant to SCS; and/or has undergone nasal polypectomy within 6 months prior to screening, with persistent bilateral CRSwNP.
  8. Has been on a stable dosage of intranasal corticosteroids (INCS) for at least 4 weeks prior to screening;
  9. Demonstrates ≥80% adherence to mometasone furoate nasal spray (MFNS) administration during the run-in period (with a minimum of 14 days of use).

Exclusion criteria

Exclusion Criteria:

  1. Concurrent other nasal diseases or nasal symptoms;
  2. Acute upper respiratory tract infection at screening, which the investigator assesses may affect nasal symptom scoring;
  3. Severe infection requiring intravenous antibiotics and/or hospitalization within 4 weeks prior to randomization that has not yet resolved, or active infection requiring oral antibiotics within 2 weeks prior to randomization that has not yet resolved; the investigator assesses that enrollment of the participant may pose uncontrollable risks;
  4. Concurrent active parasitic infection (e.g., helminths) or suspected parasitic infection;
  5. Known or suspected history of , including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or participants with a history of such infections that have resolved but are assessed by the investigator as likely to recur frequently;
  6. Any severe or unstable disease that the investigator believes may affect the participant's safety during the study and/or hinder the participant from completing the study;
  7. Has any severe or unstable disease that, in the investigator's judgment, may affect the safety of the trial participant during the study and/or preclude the participant from completing the study, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, , hematological, or psychiatric disorders.
  8. Current or prior receipt of the following treatments:

    • Use of traditional Chinese medicine (TCM) or proprietary Chinese medicines for chronic rhinosinusitis within 1 week prior to screening;
    • Use of medium- or short-acting systemic (SCS) within 4 weeks prior to randomization, or long-acting SCS within 6 weeks prior to randomization;
    • Receipt of any systemic monoclonal antibody therapy [e.g., Stapokibart, Dupilumab, Mepolizumab, Omalizumab, Tezepelumab, etc.] within 10 weeks prior to randomization or within 5 half-lives (whichever is longer);
    • Use of systemic immunosuppressants within 4 weeks prior to randomization or within 5 half-lives (whichever is longer);
    • Initiation of leukotriene receptor antagonist (LTRA) therapy within 4 weeks prior to randomization (participants who have been receiving stable-dose LTRA therapy for at least 4 weeks prior to randomization are eligible for enrollment);
  9. For participants with concurrent asthma, the (FEV1) as a percentage of predicted value ≤ 50% during the screening/run-in period;
  10. Known allergy or intolerance to any component of the product and/or mometasone furoate nasal spray;
  11. Pregnant or lactating females;
  12. Any other conditions that the investigator deems inappropriate for the participant to participate in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    LP-003 300 mg group

    Participants will receive subcutaneous injection of LP-003 Injection at a dose of 300 mg once every 12 weeks.

    Biological: LP-003 Injection

  • Experimental
    LP-003 450 mg group

    Participants will receive subcutaneous injection of LP-003 Injection at a dose of 450 mg once every 12 weeks.

    Biological: LP-003 Injection

  • Placebo comparator
    Placebo

    Participants will receive subcutaneous injection of placebo Injection once every 12 weeks.

    Biological: Placebo of LP-003

Interventions

  • s.c. injection, Q12W

  • BiologicalPlacebo of LP-003

    s.c. injection, Q12W

06

What researchers measure

Primary outcomes

  1. Change from baseline in Nasal Polyps Score (NPS) at Week 24

    NPS is a bilateral endoscopic assessment scale for nasal polyposis, where each nasal cavity is scored from 0 to 4. The total score is the sum of the left and right sides, ranging from 0 to 8, with higher scores indicating more severe nasal polyp disease.

    Time frame: Week 24

  2. Change from baseline in Nasal Congestion Score (NCS) at Week 24

    The NCS is a patient-reported outcome measure using a 0-3 point Verbal Rating Scale (VRS). Patients rate their nasal congestion severity as 0 (no symptoms), 1 (mild symptoms), 2 (moderate symptoms), or 3 (severe symptoms). The total score ranges from 0 to 3, with higher scores indicating more severe nasal congestion.

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in NPS at each assessment visit (excluding Week 24)

    Time frame: Up to approximately 56 weeks

  2. Percentage of participants with a ≥1-point improvement in NPS from baseline

    Time frame: Up to approximately 56 weeks

  3. Percentage of participants with a ≥2-point improvement in NPS from baseline

    Time frame: Up to approximately 56 weeks

  4. Change from baseline in NCS at each assessment visit (excluding Week 24)

    Time frame: Up to approximately 56 weeks

  5. Percentage of participants with a ≥1-point improvement in NCS from baseline

    Time frame: Up to approximately 56 weeks

  6. Change from baseline in Total Score of 22-Items Sinonasal Outcome Test (SNOT-22)

    The SNOT-22 is a validated 22-items questionnaire to assess the impact of chronic rhinosinusitis on health-related quality of life (HRQoL) with a recall period of 2 weeks. There are 5 domains that could be described within SNOT-22, including nasal, ear, sleep, general and practical, and emotional; each domain was scored on a 6-category scale which ranged from 0: no problem to 5: problem as bad as it can be. The total score was the sum of response to each of the 22 questions and ranged from 0 (no disease) to 110 (worst disease), higher scores indicated worse HRQoL.

    Time frame: Up to approximately 56 weeks

  7. Incidence of adverse events (AEs)

    Time frame: Up to approximately 56 weeks

  8. Number of patients with anti-drug antibodies (ADA)

    Time frame: Up to approximately 56 weeks

  9. Serum concentrations of LP-003

    Time frame: Up to approximately 56 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2027, 13 months later.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartEst.
Jan 20, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Sep 30, 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07313917
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Jan 20, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Jie Yang
Contact
yangj@longbiopharma.com
+86 021-58372390
Luo Zhang
principal investigator · Beijing Tongren Hospital Affiliated to Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion